	US 11,981,737 B2
	Anti-HLA-G antibodies and use thereof
Jens Fischer, Penzberg (DE); Meher Majety, Penzberg (DE); Stefan Dengl, Penzberg (DE); Georg Tiefenthaler, Penzberg (DE); Stefan Klostermann, Penzberg (DE); Claudia Kirstenpfad, Penzberg (DE); Esther Koenigsberger, Penzberg (DE); and Francesca Ros, Penzberg (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on May 17, 2019, as Appl. No. 16/415,979.
Application 16/415,979 is a continuation of application No. PCT/EP2017/079429, filed on Nov. 16, 2017.
Claims priority of application No. 16199620 (EP), filed on Nov. 18, 2016.
Prior Publication US 2020/0102389 A1, Apr. 2, 2020
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/2833 (2013.01) [G01N 33/57484 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); G01N 2333/70539 (2013.01)]

9 Claims

1. An isolated antibody that binds to human HLA-G, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.